NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California (NASDAQ:PACB) posted its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $19.40 million for the quarter, compared to the consensus estimate of $23.97 million. Pacific Biosciences of California had a negative return on equity of 91.11% and a negative net margin of 105.22%. Pacific Biosciences of California's quarterly revenue was down 22.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) earnings per share. View Pacific Biosciences of California's Earnings History.

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

2 brokers have issued 12 month price objectives for Pacific Biosciences of California's stock. Their predictions range from $4.00 to $6.80. On average, they anticipate Pacific Biosciences of California's share price to reach $5.40 in the next twelve months. This suggests a possible upside of 44.0% from the stock's current price. View Analyst Ratings for Pacific Biosciences of California.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Media headlines about PACB stock have trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a news impact score of 0.08 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 44.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $3.75.

Pacific Biosciences of California has a market capitalization of $493.22 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]